8-K: Microbot Medical Settles 2020 Lawsuit, Secures Insurance Coverage for Cash Portion

Microbot Medical has reached a settlement agreement resolving a 2020 lawsuit, with the cash portion of the settlement covered by the company's insurance.

Summary

• Microbot Medical has entered into a Settlement Agreement and Release with Empery Asset Master Ltd., Empery Tax Efficient, LP, Empery Tax Efficient III, LP, and Hudson Bay Master Fund Ltd. to resolve a lawsuit initiated in 2020.
• The lawsuit alleged that Microbot Medical breached representations and warranties related to a 2017 equity financing and sought rescission of the Securities Purchase Agreement and return of the $6.75 million purchase price.
• The settlement requires Microbot Medical to pay a total of $2,154,000, consisting of a $1,100,000 cash payment covered by insurance and 1,005,965 shares of restricted common stock.
• The number of shares was calculated using a formula based on the closing price of the company's common stock on the effective date of the agreement, January 26, 2024, multiplied by 0.825.
• Microbot Medical is also obligated to file a registration statement for the resale of these shares within 30 days and use reasonable efforts to have it declared effective by the SEC within 60 to 90 days.
• Both parties have agreed to release each other from all claims related to the 2017 financing, the Securities Purchase Agreement, and the lawsuit.
• The plaintiffs will discontinue the lawsuit with prejudice within three business days of receiving the total settlement amount.
• Microbot Medical submitted an Investigational Device Exemption (IDE) application to the FDA on January 29, 2024, to commence its pivotal clinical trial in humans.

Sentiment

Score: 7

Explanation: The settlement is a positive development as it removes a legal overhang and preserves cash, but the issuance of new shares is a slight negative. The focus on clinical trials is encouraging.

Positives

• The settlement resolves a long-standing legal dispute, removing uncertainty for the company.
• The cash portion of the settlement is covered by insurance, preserving the company's cash position.
• The company is moving forward with its clinical trial plans, as evidenced by the IDE submission to the FDA.
• The settlement includes a full release of claims for both parties, preventing future litigation related to the matter.

Negatives

• The company is issuing 1,005,965 shares of restricted stock as part of the settlement, which could dilute existing shareholders.
• There are potential cash penalties if the company fails to register the shares or remove restrictions on them in a timely manner.
• The company had to pay $2,154,000 to settle the lawsuit, even though the cash portion was covered by insurance.

Risks

• Failure to register the shares for resale within the specified timeframe could result in cash penalties.
• Delays in obtaining SEC effectiveness for the registration statement could also lead to penalties.
• The issuance of new shares could dilute the value of existing shares.
• The company is still pre-clinical and faces risks inherent in the development and commercialization of its products.

Future Outlook

The company is focused on upcoming milestones, including the commencement of its first in-human clinical trial, and believes resolving the lawsuit allows them to move forward with these plans.

Management Comments

• Harel Gadot, CEO, President and Chairman of Microbot Medical, stated that resolving the matter while maintaining the company's cash position is in the best interest of shareholders.
• He also mentioned the focus on upcoming milestones, including the IDE submission with the FDA and planned commencement of the first in human clinical trial.

Industry Context

This settlement allows Microbot Medical to focus on its core business of developing robotic surgical systems, which is a growing area in the medical device industry. The company's focus on endovascular procedures aligns with the trend towards minimally invasive surgeries.

Comparison to Industry Standards

• Settlements of this nature are not uncommon in the biotech and medical device industries, especially after disputes over financing agreements.
• The use of a combination of cash and stock in settlements is also a common practice.
• The requirement to register the shares for resale is standard in such agreements to allow the recipients to liquidate their holdings.
• The timeline for filing and achieving effectiveness of the registration statement is also typical for these types of transactions.
• The penalties for failing to meet registration deadlines are also standard in these types of agreements.

Legal Proceedings

• The document details the settlement of a lawsuit filed against Microbot Medical in 2020.
• The lawsuit alleged breaches of representations and warranties related to a 2017 equity financing.

Stakeholder Impact

• Shareholders will benefit from the resolution of the lawsuit and the preservation of the company's cash position.
• However, the issuance of new shares could dilute the value of existing shares.
• Employees will benefit from the company's continued focus on its core business and clinical trial plans.
• Customers and suppliers will not be directly impacted by this settlement.

Next Steps

• Microbot Medical will file a registration statement for the resale of the shares within 30 days.
• The company will use reasonable best efforts to have the registration statement declared effective by the SEC within 60 to 90 days.
• The plaintiffs will file a stipulation discontinuing the lawsuit with prejudice within three business days of receiving the total settlement amount.
• The company will continue to focus on its clinical trial plans, including the commencement of its first in-human clinical trial.

Key Dates

Keywords

settlement, lawsuit, equity financing, registration rights, restricted stock, IDE application, clinical trial, insurance, SEC, litigation